Tool may help identify which patients with clonal hematopoiesis will develop cancer
Click Here to Manage Email Alerts
NEW ORLEANS — A new clinical tool can help identify which patients with clonal hematopoiesis are at highest risk for progression to cancer, according to study results presented at ASH Annual Meeting and Exposition.
An estimated 15% of individuals aged older than 65 years have clonal hematopoiesis, a condition characterized by genetic mutations associated with leukemia or other hematologic malignancies. However, only about 4% will develop cancer.
The lack of an effective strategy to predict which individuals would develop cancer has made it difficult for clinicians to advise patients with clonal hematopoiesis.
A computational algorithm developed by Lachelle D. Weeks, MD, PhD, hematologist-oncologist at Dana-Farber Cancer Center and instructor of medicine at Harvard Medical School, and colleagues demonstrated the potential to determine which people with clonal hematopoiesis are at high risk for blood cancers.
Healio spoke with Weeks about the findings and their potential implications.
References:
- New clinical tool for clonal hematopoiesis identified patients at high risk for blood cancer (press release). Available at: https://www.dana-farber.org/newsroom/news-releases/2022/new-clinical-tool-for-clonal-hematopoiesis-identifies-patients-at-high-risk-for-blood-cancer/. Published Dec. 12, 2022. Accessed Dec. 19, 2022.
- Weeks LD, et al. Abstract 926. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Collapse
Weeks LD, et al. Abstract 926. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Read more about
Click Here to Manage Email Alerts